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OBJECTIVES: To assess and compare patients’ access to biologic anti-RA drugs in 
selected CEE countries (Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Poland, 
Romania, Russia, Serbia, Slovakia, Slovenia) and to analyse the determinants of dif-
ferences between countries. METHODS: This is a multi-country survey study, based 
on a combination of desk research and direct contact with national RA stakeholders. 
Data was collected using a pre-deﬁned questionnaire. Affordability was measured 
using affordability index, calculated comparing the health care expenditures index to 
the price index, using Poland as an index of 1. A higher index indicates more limited 
affordability. RESULTS: The percentage of patients on biologic treatment in 2009 
was highest in Hungary (5%), followed by Slovenia (4.5%), Slovakia (3.5%), Czech 
(2.92%), Romania (2.19%), Estonia (1.8%), Croatia (1.4%) and Serbia (1.3%), 
lowest in Poland (1%). Inﬂiximab, etanercept, adalimumab and rituximab are 
included in the reimbursement system in all countries (latest in Bulgaria), abatacept 
and tocilizumab—only in Slovakia. In Slovenia public payer covered 75% of the price, 
25% was covered by supplementary health insurance; in Bulgaria public payer covered 
50% of etanercept and adalimumab costs, and 75% of rituximab cost. In other 
countries biological drugs were reimbursed in 100%. Affordability index for biologic 
drugs was lowest in Slovenia (0.4), followed by Hungary (0.6), Czech Rep. (0.7), 
Estonia (0.9), while countries with health care expenditures below 500 USD/capita 
(Bulgaria, Romania and Serbia) had the highest indexes (1.4–1.9). In each country 
national guidelines deﬁned which patients were eligible for biologic tretament, and 
some also deﬁned the sequence in which drugs should be used. DAS28 of over 5.1. 
and failure of 2 or more disease-modifying anti-RA drugs, including methotrexate, 
are commonly used criteria. CONCLUSIONS: The most important factors of limited 
access to biologic anti-RA treatment CEE region are macroeconomic conditions and 
restrictive treatment guidelines.
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OBJECTIVES: Payers may employ utilization management tools that restrict access 
to FDA-approved therapies in favor of off-label therapies for treating disorders such 
as ﬁbromyalgia (FM). It is appropriate to review the body of evidence that exists to 
support these decisions. We assessed the quality and quantity of published randomized 
clinical trials (RCTs), as well as reviewed the trial evidence presented in compendia 
and guidelines, for commonly prescribed FM treatments. METHODS: A literature 
review was conducted using MEDLINE, Cochrane Library, and EMBASE for FM 
RCTs published January 2000 to June 2009. Two raters reviewed the quality of each 
RCT using the Jadad Quality Score. RCTs published prior to 2000 and cited in sys-
tematic reviews with published Jadad scores supplemented the review. Trial evidence 
cited in Drugdex and AHFS-DI compendia and the 2005 American Pain Society (APS) 
guideline were also reviewed. RESULTS: The 2000–2009 literature review yielded 19 
RCTs; the supplemental review yielded an additional 14 RCTs. When comparing 
across FM treatments, the FDA-approved therapies reported high-quality scores and 
had many more study subjects reported in published RCTs compared to off-label 
therapies. A review of compendia showed pregabalin was the only FM therapy cited 
in both Drugdex and AHFS-DI. However, the APS guideline, last updated in 2005, 
recommended off-label therapies and cited gabapentin and the FDA-approved prega-
balin as “experimental” treatments for FM. The off-label therapies nortriptyline and 
cyclobenzaprine were not listed as treatments for FM in either compendia, and many 
off-label and FDA-approved therapies were not speciﬁcally cited in the guideline. 
CONCLUSIONS: Formulary decision-makers should carefully consider the currency 
and quality of the body of evidence cited in compendia and guidelines, and should 
compare listings to recent high-quality published RCTs when considering utilization 
management tools for the treatment of FM.
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OBJECTIVES: Little is known about the burden of rheumatoid-arthritis (RA). The 
study objectives were to present an overview of the burden of RA in Ontario using 
survey and administrative data. METHODS: Records of all Ontarians who partici-
pated in the Canadian Community Health Survey (CCHS), cycle 1.1 (2000/2001) and 
provided consent to data linkage were linked to the Ontario Health Insurance Program 
(OHIP) physician claims database and the Discharge Abstract Database (DAD) In-
Patient (i.e. hospitalization) and Day-Procedure databases. Two criteria were used to 
identify RA patients (N = 233): 1) self-reported physician-diagnosed RA in CCHS; 
and 2) ICD-9 diagnosis code of RA in OHIP. A control group matched by age and 
gender was created (N = 688). Socio-demographic variables, medical characteristics, 
health-related quality of life and one-year physician, day procedures and hospitaliza-
tion costs were determined. CCHS sample weights were applied to represent the 
Ontario population. Logistic regressions, Tobit and Generalized Linear Model models 
were used to identify predictors of medical characteristics, utility and cost data, 
respectively. Bootstrap techniques were applied for the cost analyses. RESULTS: The 
mean age of the population was 59 years old and 75% were female. Compared to the 
control group, RA Individuals were statistically more likely to: be obese, reside in an 
urban community, be female, have more comorbidities and a lower HRQoL. No 
statistical differences were observed in terms of costs even after covariate adjustment. 
CONCLUSIONS: Although drug costs were not included, these results indicate that 
the burden of RA is considerable.
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OBJECTIVES: The aim was to estimate the prevalence of rheumatoid arthritis (RA) 
between 2003 and 2007, examine the real-life treatment patterns, and estimate the 
cost of managing RA in Taiwan. METHODS: A retrospective analysis of the medical 
claims data from the National Health Insurance Research Database (NHIRD) from 
years 2003–2007 was conducted. Eligible patients were deﬁned as having 1) an out-
patient visit with ICD9 code = 714.0; 2) an inpatient admission with the ICD9 code 
= 714.0; or 3) a catastrophic card for RA. Medication records were extracted. Informa-
tion on treatment with NSAIDs, DMARDs, and bio-DMARDs was extracted from 
the recorded diagnosis. RESULTS: The prevalence rate of RA in Taiwan was found 
to be around 0.4%. Majority of the patients identiﬁed were on NSAIDs (∼81%), while 
the proportion of patients treated with DMARDs increased from 26% to >35% during 
the study period. In the ﬁrst year from initial diagnosis, 13% to 17% patients were 
treated with DMARDs and 75% with NSAIDs. Etanercept was the ﬁrst bio-DMARD 
approved for use in RA in Taiwan in 2003; since its introduction, both the number 
and proportion of RA patients treated with etanercept increased sharply to 2284 by 
the end of 2007. Out of 2284, TB was reported in 55 patients, 45 of which were new 
cases. The average duration from starting etanercept to the date of a TB diagnosis 
was 461 days. The mean cost per person increased from 379 in 2003 to US$703 in 
2007, i.e. nearly doubled. CONCLUSIONS: The ﬁndings provide an estimate of RA 
prevalence and show the signiﬁcant medical cost of managing RA to the national 
health care system in Taiwan. A key limitation of the study is that the claims data do 
not have biological information on disease status and the medical reasons for treat-
ment failure or discontinuation.
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OBJECTIVES: Little is known about the health status and costs of individuals with 
osteo-arthritis (OA) in Ontario. The study objectives were to estimate the burden of 
OA in Ontario using health survey and administrative data. METHODS: The records 
of all Ontarians who participated in the Canadian Community Health Survey (CCHS), 
cycle 1.1 (2000/2001) and provided consent to data linkage were linked to the Ontario 
Health Insurance Program (OHIP) physician claims database and the Discharge 
Abstract Database (DAD) In-Patient (i.e. hospitalization) and Day-Procedure data-
bases. OA individuals (N = 4,331) were identiﬁed using CCHS 1.1. A control group 
matched by age and gender was created (N = 1,477). Socio-demographic variables, 
medical characteristics, health-related quality of life (HRQoL) and one-year physician, 
day procedures and hospitalization costs were determined. CCHS sample weights were 
applied to the data to represent the Ontario population. Logistic regressions, Tobit 
and Generalized Linear Model models were used to identify predictors of medical 
characteristics, utility and cost data, respectively. Bootstrap techniques were applied 
for the cost analyses. RESULTS: The mean age of the population was 66 years old 
and 74% were female. Compared to the control group, OA individuals were statisti-
